Scott T Tagawa

Scott T Tagawa

UNVERIFIED PROFILE

Are you Scott T Tagawa?   Register this Author

Register author
Scott T Tagawa

Scott T Tagawa

Publications by authors named "Scott T Tagawa"

Are you Scott T Tagawa?   Register this Author

94Publications

2886Reads

41Profile Views

Clinical Significance of AR-V567es in Prostate Cancer-Response.

Clin Cancer Res 2019 Oct;25(19):6010-6011

Weill Cornell Medicine/Meyer Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1820DOI Listing
October 2019

Clinical features of neuroendocrine prostate cancer.

Eur J Cancer 2019 Sep 13;121:7-18. Epub 2019 Sep 13.

Department of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, USA; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.08.011DOI Listing
September 2019

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

N Engl J Med 2019 07;381(4):338-348

From Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Université Paris-Saclay, Villejuif, France (Y.L.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Genitourinary and Gynecological Cancer Unit, Centro Integral Oncológico Clara Campal, Madrid (J.G.-D.), Hospital Clinic Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (B.M.), and Hospital Universitario Marques de Valdecilla, Santander (I.D.) - all in Spain; the Institute of Cancer Research, Sutton, London (R.H.); the Levine Cancer Institute, Atrium Health, Charlotte, NC (E.B.); Virginia Oncology Associates, US Oncology Research, Norfolk (M.F.); Norton Healthcare, Louisville, KY (A.R.); the Altai Regional Cancer Center, Barnaul, Russia (S.V.); the Penn State Cancer Institute, Hershey (M.J.), and Janssen Research and Development, Spring House (B.Z., A.S.-W., A.O., A.A.) - both in Pennsylvania; Weill Cornell Medical College, New York (S.T.T.); University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City (Y.Z.); Janssen Research and Development, Beerse, Belgium (K.S., P.D.P.); and the University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1817323DOI Listing
July 2019

Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.

Phys Biol 2019 03 22;16(3):036003. Epub 2019 Mar 22.

Department of Medicine, Hematology/Oncology, Weill Cornell Medicine, New York, NY, United States of America. Author to whom any correspondence should be addressed.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1478-3975/ab073aDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555137PMC
March 2019

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

J Clin Oncol 2018 Sep 5:JCO1800606. Epub 2018 Sep 5.

Justin E. Bekelman and Neha Vapiwala, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ronald C. Chen, University of North Carolina at Chapel Hill, Chapel Hill; Stephen J. Freedland, Durham VA Medical Center, Durham, NC; Thomas M. Pisansky, Mayo Clinic, Rochester, MN; Antonio Finelli, Princess Margaret Cancer Centre, University Health Network; Andrew Feifer, Trillium Health Partners, University of Toronto; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Paul L. Nguyen, Dana-Farber Cancer Institute, Boston, MA; Scott T. Tagawa, Weill Cornell Medicine, New York, NY; Silke Gillessen, Kantonsspital St Gallen, St Gallen, Switzerland; Todd M. Morgan, University of Michigan, Ann Arbor, MI; Glenn Liu, University of Wisconsin Carbone Cancer Center, Madison, WI; John J. Haluschak, Kettering Medical Center-Pavillon, Kettering; Andrew Stephenson, Cleveland Clinic, Cleveland, OH; Karim Touijer, Memorial Sloan Kettering Cancer Center, New York, NY; Terry Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME; and Stephen J. Freedland, Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00606
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00606DOI Listing
September 2018

Antibody-Drug Conjugates in Bladder Cancer.

Bladder Cancer 2018 Jul 30;4(3):247-259. Epub 2018 Jul 30.

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-180169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087439PMC
July 2018

A critical review on ramucirumab in the treatment of advanced urothelial cancer.

Future Oncol 2018 May 12;14(11):1049-1061. Epub 2017 Dec 12.

Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0473DOI Listing
May 2018

Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.

Urol Oncol 2018 01 5;36(1):9.e11-9.e17. Epub 2017 Oct 5.

Division of Hematology and Medical Oncology, Weill-Cornell Medicine, New York, NY; Department of Urology, Weill-Cornell Medicine, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793883PMC
January 2018

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Oct 20;35(28):3181-3188. Epub 2017 Jun 20.

Emmanuel S. Antonarakis and Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Scott T. Tagawa, Giuseppe Galletti, Daniel Worroll, Karla Ballman, Ada Gjyrezi, Shinsuke Tasaki, Luigi Portella, Yang Bai, Brian J. Kirby, David M. Nanus, and Paraskevi Giannakakou, Weill Cornell Medicine/Meyer Cancer Center; Che-Kai Tsao, Mount Sinai Medical Center, New York; Timothy B. Lannin, Shalu Suri, Conor N. Gruber, Erica D. Pratt, and Brian J. Kirby, Cornell University, Ithaca, NY; Marie Vanhuyse, Medical Oncology, Montréal General Hospital; Fred Saad, University of Montreal Hospital Center, Montreal; John Stewart, Atef Zaher, and Wei Zhou, Sanofi, Laval, Quebec, Canada; Guru Sonpavde, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Scott North, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada; Costantine Albany, Indiana University School of Medicine, Indianapolis, IN; and Ted Szatrowski, Sanofi, Bridgewater, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.4138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791829PMC
October 2017

Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.

Cancer Treat Rev 2017 Jun 8;57:16-27. Epub 2017 May 8.

Weill Cornell Medicine, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.04.008DOI Listing
June 2017

Trimodality therapy in variant urothelial carcinoma: choose wisely.

Transl Androl Urol 2017 Apr;6(2):322-325

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2017.03.59DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422701PMC
April 2017

Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

Expert Opin Biol Ther 2017 02 20;17(2):135-149. Epub 2016 Nov 20.

a Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1258398DOI Listing
February 2017

Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer.

Lancet 2017 01 8;389(10064):6-7. Epub 2016 Dec 8.

Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill-Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)32516-8DOI Listing
January 2017

Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Nat Genet 2016 12 17;48(12):1490-1499. Epub 2016 Oct 17.

Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549141PMC
December 2016

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Curr Radiopharm 2016 ;9(1):44-53

Division of Nuclear Medicine and Molecular Imaging, 525 East 68th Street, STARR-221, New York, NY 10065.

View Article

Download full-text PDF

Source
September 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.

J Clin Endocrinol Metab 2016 Mar 15;101(3):981-7. Epub 2016 Jan 15.

Departments of Surgery (M.J.P.C., D.A.K., T.B., A.A., R.Z., T.J.F.), Pathology and Laboratory Medicine (T.S., Y.-F.L.), Urology (H.L., S.T.T., N.H.B.), Nuclear Medicine (Y.S.J.), and Medicine (A.M., S.T.T.); New York Presbyterian Hospital-Weill Cornell Medical College and Department of Physiology and Biophysics (M.J.P.C., O.E.), Weill Cornell Medical College-Institute for Computational Biomedicine, New York, New York 10065; and HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al-Saud Institute for Computational Biomedicine (O.E.), Weill Cornell Medical College, New York, New York 10021.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2015-4021DOI Listing
March 2016

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Clin Genitourin Cancer 2016 Feb 19;14(1):e75-9. Epub 2015 Oct 19.

Division of Hematology and Medical Oncology, Weill-Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.10.002DOI Listing
February 2016

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.

Asian J Androl 2014 Jul-Aug;16(4):568-9

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/1008-682X.127822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104084PMC
May 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Novel molecular targets for urothelial carcinoma.

Expert Opin Ther Targets 2015 Apr 30;19(4):515-25. Epub 2015 Jan 30.

Weill Cornell Medical College, Division of Hematology and Medical Oncology, Department of Medicine , New York, NY , USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2014.987662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406627PMC
April 2015

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

PLoS One 2013 27;8(12):e85143. Epub 2013 Dec 27.

Deparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America ; Department of Urology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085143PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874033PMC
February 2015

The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.

Curr Treat Options Oncol 2015 Feb;16(2)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 525 East 68th Street, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-014-0324-2
Publisher Site
http://dx.doi.org/10.1007/s11864-014-0324-2DOI Listing
February 2015

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.

Onco Targets Ther 2014 3;7:2227-36. Epub 2014 Dec 3.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA ; Department of Urology, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.dovepress.com/microtubule-inhibitor-based-antibod
Publisher Site
http://dx.doi.org/10.2147/OTT.S46887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259504PMC
December 2014

ERG induces taxane resistance in castration-resistant prostate cancer.

Nat Commun 2014 Nov 25;5:5548. Epub 2014 Nov 25.

1] Institute of Precision Medicine of Weill Cornell Medical College and New York-Presbyterian Hospital, New York, New York 10065, USA [2] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA [3] Weill Cornell Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244604PMC
November 2014

Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle.

Authors:
Scott T Tagawa

J Clin Oncol 2014 Oct 15;32(30):3360-4. Epub 2014 Sep 15.

Weill Cornell Medical College, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.5100DOI Listing
October 2014

Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Mol Diagn Ther 2014 Aug;18(4):389-402

Division of Hematology and Medical Oncology and the Weill Cornell Cancer Center, Weill Cornell Medical College, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-014-0101-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149177PMC
August 2014

Immunologics and chemotherapeutics for renal cell carcinoma.

Semin Intervent Radiol 2014 Mar;31(1):91-7

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0033-1363848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930661PMC
March 2014

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Cancer Chemother Pharmacol 2013 Oct 7;72(4):909-16. Epub 2013 Aug 7.

Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3008 AE, Rotterdam, The Netherlands,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00280-013-2250
Web Search
http://link.springer.com/10.1007/s00280-013-2250-6
Publisher Site
http://dx.doi.org/10.1007/s00280-013-2250-6DOI Listing
October 2013

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Clin Cancer Res 2013 Sep 28;19(18):5182-91. Epub 2013 May 28.

Authors' Affiliations: Weill Cornell Medical College (WCMC); Weill Cornell Cancer Center; Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York; and University of North Carolina Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778101PMC
September 2013

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Front Oncol 2013 26;3:214. Epub 2013 Aug 26.

Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College , New York, NY , USA ; Department of Urology, Weill Cornell Medical College , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752585PMC
August 2013

PSMA-targeted dendrimers: a patent evaluation (WO2012078534).

Expert Opin Ther Pat 2013 May 13;23(5):665-8. Epub 2013 Apr 13.

Weill Cornell Medical College, Division of Hematology and Medical Oncology, Department of Medicine, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543776.2013.789501DOI Listing
May 2013

Prostate-specific membrane antigen-based imaging.

Urol Oncol 2013 Feb 31;31(2):144-54. Epub 2012 May 31.

Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2012.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461099PMC
February 2013

2-weekly versus 3-weekly docetaxel for prostate cancer.

Lancet Oncol 2013 Feb 4;14(2):98-9. Epub 2013 Jan 4.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70579-XDOI Listing
February 2013

Challenges in recognizing treatment-related neuroendocrine prostate cancer.

J Clin Oncol 2012 Dec 19;30(36):e386-9. Epub 2012 Nov 19.

Weill Cornell Cancer Center; Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.41.5166
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.41.5166DOI Listing
December 2012

Isolation and characterization of circulating tumor cells in prostate cancer.

Front Oncol 2012 11;2:131. Epub 2012 Oct 11.

Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2012.00131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468833PMC
October 2012

The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.

Prostate Cancer 2012 24;2012:280278. Epub 2012 Apr 24.

Department of Radiation Oncology, Stitch Radiation Center, Weill Cornell Medical College, 525 East 68th Street, P.O. Box 575, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/pc/2012/280278/
Publisher Site
http://dx.doi.org/10.1155/2012/280278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348643PMC
August 2012

Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Adv Urol 2012 28;2012:921674. Epub 2012 May 28.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/921674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368159PMC
August 2012

Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?

J Urol 2012 Aug 14;188(2):358-60. Epub 2012 Jun 14.

Department of Genitourinary Medical Oncology, Mount Sinai School of Medicine, Tisch Cancer Institute, New York, New York, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002253471203785
Publisher Site
http://dx.doi.org/10.1016/j.juro.2012.05.026DOI Listing
August 2012

Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).

BJU Int 2012 Apr 28;109(7):968-85. Epub 2011 Oct 28.

Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2011.10643.xDOI Listing
April 2012

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

Urol Oncol 2011 Nov-Dec;29(6):676-81. Epub 2010 May 7.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S107814391000003
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2009.12.023DOI Listing
March 2012

Prostate-specific membrane antigen-based therapeutics.

Adv Urol 2012 17;2012:973820. Epub 2011 Jul 17.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, 525 E. 68th Street, Box 403, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/973820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145341PMC
November 2011

Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.

Asian J Androl 2011 Nov 22;13(6):785-6. Epub 2011 Aug 22.

Department of Medicine, Weill Cornell Medical College, Weill Cornell Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/aja.2011.113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739559PMC
November 2011

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

BJU Int 2011 Sep 13;108(5):679-86. Epub 2010 Dec 13.

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1464-410X.2010.09947.x
Publisher Site
http://dx.doi.org/10.1111/j.1464-410X.2010.09947.xDOI Listing
September 2011

New therapies for castration-resistant prostate cancer: efficacy and safety.

Eur Urol 2011 Aug 4;60(2):279-90. Epub 2011 May 4.

Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2011.04.038DOI Listing
August 2011

Editorial comment.

J Urol 2011 Jan 12;185(1):59. Epub 2010 Nov 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.09.134DOI Listing
January 2011

PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.

Semin Nucl Med 2011 Jan;41(1):29-44

PET and Cyclotron Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2010.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392994PMC
January 2011

Editorial comment.

Authors:
Scott T Tagawa

J Urol 2009 Sep 17;182(3):906. Epub 2009 Jul 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.05.110DOI Listing
September 2009

Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy.

BJU Int 2008 Nov 29;102(9):1086-91. Epub 2008 Jul 29.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2008.07780.xDOI Listing
November 2008

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

Cancer 2006 Mar;106(6):1353-7

Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.21748
Publisher Site
http://dx.doi.org/10.1002/cncr.21748DOI Listing
March 2006

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).

Invest New Drugs 2004 Aug;22(3):291-7

University of Southern California-Kenneth Norris Jr. Comprehensive Cancer Center and California Cancer Medical Center, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:DRUG.0000026255.34988.96DOI Listing
August 2004

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma.

Cancer 2003 Jul;98(1):144-54

Department of Medicine, Keck-University of Southern California School of Medicine, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11462DOI Listing
July 2003